B. Braun operates through three divisions: Hospital Care (infusion, nutrition, pain therapy, and regional anesthesia focus), Aesculap (surgical and interventional treatment), and Avitum (renal care). The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety.
Cyborg Score Rationale
B. Braun generated €9.14 billion in revenue with R&D expenditure of €526 million and 64,262 employees. The company has strong product innovation and strategic acquisition capability, though recent regulatory challenges including an FDA early alert (March 2026) and ongoing litigation present headwinds.
Top Insights
B. Braun acquired True Digital Surgery (September 2025) to expand its digital microsurgery portfolio and strengthen its Aesculap surgical division, having previously held a minority stake.
FDA issued an early alert (March 2026) for certain Streamline Airless System Hemodialysis Bloodlines and B3 Low Volume Bloodlines due to manufacturing defect with tubing resin changes causing air bubbles in arterial bloodlines.
B. Braun Medical launched Introcan Safety 2 IV Catheter with Multi-Access Blood Control, providing automatic needlestick protection and blood control features to reduce bloodborne pathogen exposure.
Following supply disruptions from Hurricane Milton (October 2024), B. Braun increased IV fluid production by 20% at Florida and California facilities and expanded tubing/valve manufacturing in Pennsylvania, offering 30 million additional IV sets annually.
Named Competitors
Infusion & Renal Products — Healthcare services with infusion therapy and renal care products
Surgical Instruments & Devices — Leading medical device manufacturer with broad surgical and diagnostic portfolio
Medical Devices & Pharmaceuticals — Diversified healthcare company with medical devices, pharmaceuticals, and consumer health
IV Solutions & Infusion — IV fluids, infusion therapy, and renal care solutions
Recent Developments
(March 2026) FDA early alert issued for hemodialysis bloodlines due to tubing resin defect
(September 2025) B. Braun acquired True Digital Surgery to expand robotic microsurgery capabilities
(May 2026) Pedestrian bridge promotion initiative announced for Rubí City headquarters
(October 2024) Introcan Safety 2 IV Catheter with Multi-Access Blood Control launched
Open the full interactive B. Braun SE report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.